Apple described Siri AI as a completely reimagined Siri integrated seamlessly across platforms and built to be private and personal to the user’s context. Management said response in developer and public betas was “phenomenal,” with early user reviews described as having “exceptional” feedback.

Lilly stated the Medicare GLP-1 Bridge program launched July 1 and provides insurance coverage for GLP-1s for obesity at a low out-of-pocket price of $50 per month for 20 million eligible Americans. Management said coverage for obesity medicines increased by 35% in the U.S. with the Bridge program.

Helios was launched combining EPYC Venice CPUs, MI450-Series GPUs, Pensando networking, and ROCm software. AMD claimed Helios delivers up to 15% more throughput at the same rack power and up to 30% more tokens per dollar versus the competition (as stated).

Mastercard stated switching penetration reached 72% and emphasized network architecture flexibility to meet market needs while driving the virtuous cycle. The Central Bank of the UAE subsidiary Al Etihad Payments is partnering with Mastercard to build UAE switching technology for the next phase of domestic payments infrastructure.

Adjusted EPS was $3.65 in Q2, $0.06 above the guidance midpoint. Total net revenues were nearly $17 billion, beating expectations by $300 million and up 10.2% year over year (with a 0.7% favorable FX impact mentioned).

$3B structural cost reductions

Across FY2026, management framed Azure and infrastructure efficiency as the foundation for agentic platforms, then emphasized compounding adoption in Copilot and developer tooling. The year’s narrative shifted from building capacity and governance to demonstrating usage intensity, model/harness modularity, and emerging usage-based monetization patterns.

Microsoft 365 Copilot is moving from pilots to large-scale, enterprise-wide deployments, with paid adoption at enterprise scale and time-to-value collapsing. The monetization strategy combines seat expansion, higher-value SKUs like E7, and a growing consumption-based model, signaling a multi-pronged approach as deployments broaden and governance features (Agent 365) address security and token spend.

AMD does not provide a fixed 2027 gigawatt target in the transcripts; instead it frames the ramp through growth rates and the Helios ramp trajectory, signaling that the AI datacenter demand will drive the ramp rather than a single GW target. Management indicates double-digit billions in revenue per gigawatt within a broader data-center AI growth narrative, underscoring the mix and capacity timing as primary upside and risk drivers.

Arista reports momentum in AI-labs adoption through its AI fabrics ecosystem, noting Etherlink momentum exceeding 100 cumulative customers and signaling a security-focused collaboration with leading model providers and vendors. Management stops short of a firm Q4 10%+ target, instead highlighting flexibility in product ships and acknowledging ongoing onboarding cycles as the company positions itself for larger AI deployments.

Palantir outlines management's take on the Sovereignty boot camp, highlighting it as an education-driven response to surging demand in the AI era. The discussion emphasizes practical sovereignty implementations, cross-functional adoption, and a strategic push to educate customers on regaining control over data, contracts, and compute.

Lilly’s U.S. launch faced early execution and data-noise challenges, with an inflection expected as access and physician adoption ramp up. Outside the U.S., Novo's entry is likely to raise competitive pressure, but market expansion and payer access remain key to sustained growth, as UAE experience suggests.

Merck frames the major PCSK9 growth potential as expanding treatment to under-treated and PCSK9-naive patients, not merely switching existing injectables. Adoption in primary care will hinge on education, guideline-aligned messaging, and access-channel expansion (including MFN-driven TrumpRx), with a measured ramp expected before a long-term blockbuster trajectory materializes; that aligns with a long-term, durable growth trajectory across payers and patients.

Q2 2026 revenue grew 48% vs Q2 2025 to $48B+ (implied by 48% growth and guidance context), driven by Zepbound and Mounjaro.

Management tied record customer demand and profitability to AI waves progressing from training to inference to agentic and physical AI.

Management stated that the 6 key growth drivers grew at an aggregate rate of 26% year-over-year.

CEO cited the U.S. homecare business as the majority driver of Americas margin pressure and said portfolio pruning has not been enough to overcome headwinds.

CEO emphasized that AVs must be deployed market-by-market due to regulation and variable ride-hailing patterns.

Delivered almost $2.0B revenue in Q2 2026 (about $1.92B reported), just below the midpoint of guidance, with 53% YoY and 4% sequential growth.

Electrical Americas remained the clearest execution priority, with more than $1 billion invested in capacity expansion and “2 dozen” projects being brought online.

Headline revenues were up 24% year-over-year in Q2, with strong incremental margins of 46% (after impact from the CAM acquisition).

ECFS data reinforced ALYFTREK as best restoring CFTR function among available CFTR modulators.

Q2 2026 revenue grew 17% year-over-year to $3.6 billion, exceeding the high end of outlook.